Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
- 26 August 2013
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 110 (37), 15001-15006
- https://doi.org/10.1073/pnas.1312772110
Abstract
Hepatitis C virus (HCV) persistence is facilitated by exhaustion of CD8+ T cells that express the inhibitory receptor programmed cell death 1 (PD-1). Blockade of PD-1 signaling improves in vitro proliferation of HCV-specific T lymphocytes, but whether antiviral function can be restored in infected individuals is unknown. To address this question, chimpanzees with persistent HCV infection were treated with anti–PD-1 antibodies. A significant reduction in HCV viremia was observed in one of three treated animals without apparent hepatocellular injury. Viremia rebounded in the responder animal when antibody treatment was discontinued. Control of HCV replication was associated with restoration of intrahepatic CD4+ and CD8+ T-cell immunity against multiple HCV proteins. The responder animal had a history of broader T-cell immunity to multiple HCV proteins than the two chimpanzees that did not respond to PD-1 therapy. The results suggest that successful PD-1 blockade likely requires a critical threshold of preexisting virus-specific T cells in liver and warrants consideration of therapeutic vaccination strategies in combination with PD-1 blockade to broaden narrow responses. Anti–PD-1 immunotherapy may also facilitate control of other persistent viruses, notably the hepatitis B virus where options for long-term control of virus replication are limited.Keywords
This publication has 36 references indexed in Scilit:
- CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cellsCancer Immunology, Immunotherapy, 2012
- Revealing the role of CD4+ T cells in viral immunityThe Journal of Experimental Medicine, 2012
- Towards an HIV cure: a global scientific strategyNature Reviews Immunology, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- A spatial view of the CD8+ T‐cell response: the case of HCVReviews in Medical Virology, 2011
- Pathogenesis of hepatitis B virus infectionMaterials, 2010
- Enhancing SIV-specific immunity in vivo by PD-1 blockadeNature, 2008
- Enhancing therapeutic vaccination by blocking PD-1–mediated inhibitory signals during chronic infectionThe Journal of Experimental Medicine, 2008
- Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell LymphomaThe American Journal of Surgical Pathology, 2006